Company intelligence / Profile preview
Guangzhou Regenverse Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
Guangzhou Regenverse Therapeutics is focused on research and development of biotechnology products for regenerative medicine, particularly leveraging human stem cell exosomes, brain organoids, and hepatocytes for use in cell therapy and drug development. No clinical trial results are publicly reported as of July 2025.
- Modalities
- Stem cell therapyExosome-based therapyOrganoid-based therapy
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Guangzhou Regenverse Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Regenverse Therapeutics.